Study of the Predictive Marker FLT in Patients Suffering From AML

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments.

Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment.

The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

NCT02392429

Acute Myeloid Leukemia

ACTIVE_NOT_RECRUITING PHASE2

F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)

NCT01592266

Acute Myeloid Leucemia

UNKNOWN

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

NCT02139150

Histologically-confirmed Malignancies

WITHDRAWN NA

18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma

NCT00775268

Lymphoma

TERMINATED PHASE1/PHASE2

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

NCT01143779

Advanced Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients 18 years or above at the time of inclusion;
2. Patients newly diagnosed with acute myeloid leukemia;
3. No contraindication or intolerance to any of the components of the standard chemotherapy by induction (7+3);
4. Patients able to give written informed consent.

Exclusion Criteria

1. Patients unable to tolerate decubitus position for at least 45 minutes;
2. Any previous neoplasia or other neoplasia simultaneously;
3. Previously treated buy radiotherapy, with bone marrow in the field of radiation;
4. Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before the second FLT-TEP was done.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Éric E Turcotte, MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Éric E Turcotte, MD

Role: PRINCIPAL_INVESTIGATOR

Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Centre d'imagerie moléculaire de Sherbrooke (CIMS), Centre de recherche Étienne Le-Bel